New 'Seek-and-Destroy' radiation drug enters human testing for tough cancers
NCT ID NCT04105543
Summary
This early-stage study tested a new drug, CLR 131, designed to deliver radiation directly to cancer cells. It was combined with standard external beam radiation for 12 patients whose head and neck cancer had returned. The main goal was to find a safe dose and see how well the drug reached the tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin, 53038, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.